[HTML][HTML] Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer
JCH Yang, SHI Ou, L De Petris, S Gadgeel… - Journal of Thoracic …, 2017 - Elsevier
Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
JCH Yang, SHI Ou, L De Petris… - JOURNAL OF …, 2017 - scholarworks.bwise.kr
Introduction: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
JCH Yang, SHI Ou, L De Petris, S Gadgeel, L Gandhi… - 2017 - repository.icr.ac.uk
Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer
R Govindan - 2017 - digitalcommons.wustl.edu
Introduction: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
[PDF][PDF] Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 1 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer …
S Golding, W Bordogna, B Balas, PN Morcos, A Zeaiter… - 2017 - core.ac.uk
Materials and methods: Enrolled patients had ALK-positive NSCLC and had progressed 61
on, or were intolerant to, crizotinib. Patients received oral alectinib 600 mg twice daily. The …
on, or were intolerant to, crizotinib. Patients received oral alectinib 600 mg twice daily. The …
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
JCH Yang, SHI Ou, L De Petris… - Journal of …, 2017 - cris.maastrichtuniversity.nl
Introduction: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer
JCH Yang, SHI Ou, L De Petris, S Gadgeel… - Journal of Thoracic …, 2017 - s-space.snu.ac.kr
Introduction: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
JC Yang, SI Ou, L De Petris, S Gadgeel… - Journal of Thoracic …, 2017 - europepmc.org
Methods Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC
and had progressed while taking, or could not tolerate, crizotinib. Patients received oral …
and had progressed while taking, or could not tolerate, crizotinib. Patients received oral …
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
JCH Yang, SHI Ou, L De Petris… - Journal of Thoracic …, 2017 - snucm.elsevierpure.com
Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
[引用][C] Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
JCH Yang, SHI Ou, L De Petris, S Gadgeel… - Journal of Thoracic …, 2017 - cir.nii.ac.jp
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and
NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer | CiNii Research CiNii 国立 …
NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer | CiNii Research CiNii 国立 …